# BPC-157 TB-500 FAQ: The Wolverine Blend, Questions Answered

> BPC-157 TB-500 questions answered: what the Wolverine blend is, how the two peptides differ, the synergy gap, side effects and the tumor signal, half-life, dosing context, and the FDA 503A regulatory record.

The 25 questions readers actually ask about the Wolverine blend, answered from the literature and the regulatory record — each with its source.

## Definitions and identity



## Mechanism and pairing



## Evidence and efficacy



## Safety



## Dosing, handling, and pharmacokinetics



## Regulatory and access



---

A bento board of the BPC-157 TB-500 record — each peptide read against its own studies in its own cell, the join between them left empty because no combination trial exists, and the FDA 503A status set in its own panel; no clinic behind the grid and nothing here dispensed.